Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Shares Issued (2022 - 2025)

Entrada Therapeutics has reported Shares Issued over the past 4 years, most recently at $84000.0 for Q4 2025.

  • Quarterly results put Shares Issued at $84000.0 for Q4 2025, down 96.67% from a year ago — trailing twelve months through Dec 2025 was $462000.0 (down 83.39% YoY), and the annual figure for FY2025 was $462000.0, down 83.39%.
  • Shares Issued for Q4 2025 was $84000.0 at Entrada Therapeutics, down from $378000.0 in the prior quarter.
  • Over the last five years, Shares Issued for TRDA hit a ceiling of $2.5 million in Q4 2024 and a floor of -$350000.0 in Q2 2025.
  • Median Shares Issued over the past 4 years was $245000.0 (2022), compared with a mean of $392916.7.
  • Biggest five-year swings in Shares Issued: skyrocketed 481.76% in 2024 and later tumbled 714.04% in 2025.
  • Entrada Therapeutics' Shares Issued stood at $284000.0 in 2022, then skyrocketed by 52.46% to $433000.0 in 2023, then skyrocketed by 481.76% to $2.5 million in 2024, then crashed by 96.67% to $84000.0 in 2025.
  • The last three reported values for Shares Issued were $84000.0 (Q4 2025), $378000.0 (Q3 2025), and -$350000.0 (Q2 2025) per Business Quant data.